Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | QPCT | Q16769 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzimidazole SCHEMBL3540518 | 0.98 | KDM4E (0.47) | PRKCIKDM4EMAPTRAD52MMP12 | |
| Benzimidazole SCHEMBL8010735 | 0.92 | MMP12 (0.44) | PRKCIKDM4EMAPTRAD52MMP12 | |
| Benzimidazole SCHEMBL3181865 | 0.92 | MMP12 (0.44) | PRKCIKDM4EMAPTRAD52MMP12 | |
| Benzimidazole SCHEMBL29285060 | 0.90 | MMP12 (0.43) | PRKCIKDM4EMAPTRAD52MMP12 | |
| Benzimidazole SCHEMBL5317931 | 0.88 | CTNNB1 (0.44) | PRKCIKDM4EMAPTRAD52MMP12 | |
| Benzimidazole SCHEMBL5404384 | 0.87 | PRKCI (0.52) | PRKCIKDM4EMAPTRAD52MMP12 | |
| Benzimidazole SCHEMBL29218507 | 0.87 | MMP12 (0.47) | PRKCIKDM4EMAPTRAD52MMP12 | |
| Benzimidazole SCHEMBL6009 | 0.87 | — | — | |
| Benzimidazole SCHEMBL461969 | 0.87 | SMN1; SMN2 (0.50) | PRKCIKDM4EMAPTRAD52MMP12 | |
| Benzimidazole SCHEMBL29358377 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114149419-A | Oxadiazole drug molecule for medical nursing sterilization and disinfection and preparation method and application thereof | 河南科技大学第一附属医院 | 2022-03-08 | — | — | CN | claimed |
| CN-114149419-A | Oxadiazole drug molecule for medical nursing sterilization and disinfection and preparation method and application thereof | 河南科技大学第一附属医院 | 2022-03-08 | — | — | CN | disclosed |
| EP-2560953-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2016-01-06 | — | — | EP | disclosed |
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | disclosed |
| EP-2560953-A2 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011131748-A2 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | WO | disclosed |
| US-20110262388-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | US | disclosed |
| US-7705031-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-27 | — | — | US | disclosed |
| US-20080306129-A1 | BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-7309716-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-18 | — | — | US | disclosed |
| CN-1902181-A | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMA (US) | 2007-01-24 | — | — | CN | disclosed |
| US-20050209282-A1 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209282-A1 | Benzimidazoles useful as modulators of ion channels | KCNJ11, KCNJ1, KCNJ2 | PRKCI 1004/4885KDM4E 1468/4885MAPT 4227/4885 |
| US-20110262388-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | PRKCI 1823/4885KDM4E 693/4885MAPT 3971/4885 |
| US-20080306129-A1 | BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS | KCNJ11, KCNJ1, KCNJ2 | PRKCI 1004/4885KDM4E 1468/4885MAPT 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.